CINXE.COM

<!doctype html> <html> <head>  <script src="https://cookie-cdn.cookiepro.com/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="bfd5f394-8839-4fa0-b7df-448fa9a0f885" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script>  <meta charset="UTF-8"> <title>Reduce My Recurrence</title> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta name="description" content="Get the Facts, and Act to Help Reduce Your Risk. Click here to visit ReduceRecurrence.com"> <link rel="shortcut icon" href="img/favicon.png" type="image/x-icon"> <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Amatic+SC"> <link rel="stylesheet" href="css/fonts.css"> <link href="https://fonts.googleapis.com/css?family=Raleway:400,600,xtra-Bold" rel="stylesheet"> <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.12.4/jquery.min.js"></script> <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha384-BVYiiSIFeK1dGmJRAkycuHAHRg32OmUcww7on3RYdg4Va+PmSTsz/K68vbdEjh4u" crossorigin="anonymous"> <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/css/bootstrap-theme.min.css" integrity="sha384-rHyoN1iRsVXV4nD0JutlnGaslCJuC7uwjduW9SVrLvRYooPp2bWYgmgJQIXwl/Sp" crossorigin="anonymous"> <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha384-Tc5IQib027qvyjSMfHjOMaLkfuWVxZxUPnCJA7l2mCWNIpG9mGCD8wGNIcPD7Txa" crossorigin="anonymous"></script> <link rel="stylesheet" type="text/css" href="css/style.css?v=1.0"/> <link rel="stylesheet" type="text/css" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/> <meta property="og:type" content="website" /> <meta property="og:title" content="Reduce Recurrence" /> <meta property="og:description" content="Get the Facts, and Act to Help Reduce Your Risk. Click here to visit ReduceRecurrence.com" /> <meta property="og:url" content="https://www.reducerecurrence.com/" /> <meta property="og:site_name" content="ReduceRecurrence.com" />  <meta property="og:locale" content="en_US" />  <meta name="twitter:card" content="summary_large_image" />  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-PNFRJ6X');</script>   <script async src=https://www.googletagmanager.com/gtag/js?id=G-DNWZP80JRY></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-DNWZP80JRY'); </script>  <script type='text/javascript'> (function (d, t) { var bh = d.createElement(t), s = d.getElementsByTagName(t)[0]; bh.type = 'text/javascript'; bh.src = 'https://www.bugherd.com/sidebarv2.js?apikey=dvasv18cavpxngldbkt1ag'; s.parentNode.insertBefore(bh, s); })(document, 'script'); </script>  </head> <body>  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PNFRJ6X" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>   <script type="text/javascript"> var ftRandom = Math.random()*1000000; document.write('<iframe style="position:absolute; visibility:hidden; width:1px; height:1px;" src="https://servedby.flashtalking.com/container/10749;85075;8755;iframe/?spotName=Puma_DSE_Landing_Page&cachebuster='+ftRandom+'"></iframe>'); </script> <div class="container-fluid"> <div class="row">  <header class="header"> <div class="wrapper"> <a href="index.html"><img src="img/logo.svg" class="logo" alt="Reduce My Recurrence"></a> <input class="menu-btn" type="checkbox" id="menu-btn" /> <label class="menu-icon" for="menu-btn"><span class="navicon"></span></label> <a href="pdf/discuss-guide.pdf" target="_blank"><div class="lt-grn-btn"></div></a> <a href="#form"><div class="rt-grn-btn"></div></a> <ul class="menu"> <li><a class="menu" href="#recurrence">EARLY-STAGE HER2<span class="her-2-plus">+</span> BREAST CANCER RECURRENCE FACTS</a></li> <li><a class="menu" href="#treatment">TREATMENT PLANNING</a></li> <li><a class="menu" href="#plan">MAKING A PLAN</a></li> <div class="disp"> <li><a class="menu" href="pdf/discuss-guide.pdf" target="_blank"> <img src="img/btn1icon.png" style="width:28px; padding-right: 14px;" alt="Recurrence Discussion Guide Download"/> RECURRENCE DISCUSSION GUIDE</a> </li> </div> <div class="disp"> <li><a class="menu" href="#form"><img src="img/btn2icon.png" style="width: 17px; margin-right: 65px;" alt="Sign Up to Learn More"/> SIGN UP TO LEARN MORE</a> </li> </div> </ul> </div> </header>  <div class="hero-container"> <img src="img/hero-clouds-mobile.svg" class="mobile-only" /> <img src="img/hero-clouds.svg" class="clouds desktop-only" /> </div>  <section id="recurrence"> <div class="wrapper"> <h2 class="hdrtext">EARLY-STAGE HER2<span class="her-2-plus">+</span> BREAST CANCER FACTS</h2> <div class="row"> <div class="col"> <h3 class="blue-head">HER2+ breast cancer can be aggressive and may recur even after adjuvant treatment (following surgery)<sup> 1</sup></h3> <table> <tbody> <tr> <td valign="top"><img class="arrow-bullet" src="img/arrow.png"></td> <td><div class="text">1 in 8 women in the US develops invasive breast cancer (cancer that invades tissues beyond the milk ducts and lobules of the breast)<sup class="crash">2,3</sup></div> </td> </tr> <tr> <td valign="top"><img class="arrow-bullet" src="img/arrow.png"></td> <td><div class="text">20% to 25% of these women will have HER2+ breast cancer<sup>4</sup></div> </td> </tr> <tr> <td valign="top"><img class="arrow-bullet" src="img/arrow.png"></td> <td> <div class="text"> Although adjuvant treatments (following surgery) are available specifically for early-stage HER2+ breast cancer, tumor cells can sometimes outsmart these medications and continue to grow and spread. Examples of HER2-targeted adjuvant treatments include<sup>1,5-12</sup>: </div> <ul class="bullets top-bullets"> <li>Trastuzumab</li> <li>Trastuzumab and hyaluronidase-oysk</li> <li>Pertuzumab</li> <li>Trastuzumab, pertuzumab, and hyaluronidase-zzxf</li> <li>Trastuzumab emtansine</li> </ul> </td> </tr> </tbody> </table> <h3 class="blue-head">Some factors that increase the risk of HER2+ breast cancer recurrence<sup>13,14</sup>:</h3> <ul class="bullets"> <li>Larger tumor size</li> <li>Greater number of lymph nodes that test positive for cancer</li> <li>Higher cancer stage</li> <li>Being younger</li> <li>Greater body mass index</li> <li>Being a smoker</li> </ul> </div> <div class="col"> <img src="img/infographic-small-cta.png" class="recurrence-infographic img-responsive" width="100%" alt="HER2 Breast Cancer Returns in 1 of 4 Women" /></a> </div> </div> <div class="quote-container"> <blockquote>"I wanted to do whatever I could to reduce my risk."</blockquote> <p><span class="author-dash">-</span>Debbie, breast cancer patient advocate<sup>16</sup></p> </div> </div> </section>  <div class="green full-callout"> <table class="tbl"> <tbody> <tr> <td width="10%"><img src="img/white-side-vert-lines.png"></td> <td width="80%" class="main-text">Recurrence can mean progression to metastases—cancer that has spread to other parts of the body, such as bones, lungs, brain, or liver—but there are things you can do to help reduce your risk.<sup>10,13</sup></td> <td width="10%" class="text-center"><img src="img/white-side-vert-lines.png"></td> </tr> </tbody> </table> </div>   <section id="treatment"> <div class="wrapper"> <div class="row"> <div class="col"> <h2 class="hdrtext">TREATMENT PLANNING</h2> <table> <tbody> <tr> <td valign="top"><img class="arrow-bullet" src="img/arrow.png"></td> <td class="text">Breast cancer can become resistant to treatment over time, possibly leading to recurrence<sup>10</sup></td> </tr> <tr> <td valign="top"><img class="arrow-bullet" src="img/arrow.png"></td> <td colspan="2" class="text">Different therapies block different pathways that tumors use to grow, which may be an important step in preventing breast cancer from outsmarting treatment and coming back<sup>5,7,9,17</sup></td></td> </tr> <tr> <td valign="top"><img class="arrow-bullet" src="img/arrow.png"></td> <td colspan="2" class="text">Knowing your options and participating in the development of your treatment plan can help you feel more confident that you're doing everything to reduce your risk of recurrence</td> </tr> </tbody> </table> <div class="button-container"><a href="pdf/treatment-planning-guide.pdf" target="_blank"><div class="download-btn"><img src="img/document.png"><span> DOWNLOAD A TREATMENT PLANNING GUIDE</span></div></a></div> </div> <div class="col"> <img src="img/infographic-small-cta-2.png" class="treatment-img" /> </div> </div> </div> </section>  <div class="blue full-callout"> <table class="tbl"> <tbody> <tr> <td width="10%"><img src="img/pink-side-vert-lines.png"></td> <td width="80%"> <div class="main-text">Adjuvant treatment (following surgery) may not be enough.<sup>10</sup> Ask your doctor about a treatment plan that may help reduce your risk of recurrence.</div> <div class="arrow-button-container"><a href="https://nerlynx.com/" target="_blank" class="arrow-button">See a HER2-targeted option</a></div> </td> <td width="10%" class="text-center"><img src="img/pink-side-vert-lines.png"></td> </tr> </tbody> </table> </div>  <section id="plan"> <div class="wrapper"> <h2 class="hdrtext">MAKING A PLAN TO REDUCE YOUR RISK</h2> <div class="row"> <div class="col"> <table> <tbody> <tr> <td valign="top"><img class="arrow-bullet" src="img/arrow.png"></td> <td colspan="2" class="text">Know your risk factors and your treatment plan to help you take control of your anxiety around recurrence</td> </tr> <tr> <td valign="top"><img class="arrow-bullet" src="img/arrow.png"></td> <td colspan="2" class="text">Talk to your healthcare team about what steps you should take next to reduce your chances of breast cancer returning</td> </tr> </tbody> </table> <div class="button-container"><a href="pdf/discuss-guide.pdf" target="_blank"><div class="download-btn"><img src="img/document.png"><span> RECURRENCE DISCUSSION GUIDE</span></div></a></div> </div> </div> </div> </section> <table class="tbl"> <tbody> <tr> <td colspan="4"> <div class="quote-container"> <blockquote>"I needed to feel confident that I had... done everything I could to reduce all of my risk or as much risk as possible."</blockquote> <p><span class="author-dash">-</span>Debbie, breast cancer patient advocate<sup>16</sup></p> </div> </td> </tr> </tbody> </table>   <div id="form" style="background:#edf3fb;margin:0px auto;" class="form step1"> <table class="tbl"> <tbody> <tr> <td><h2 class="hdrtext">SIGN UP TO LEARN MORE</h2></td> <td></td> <td></td> </tr> <tr> <td class="blue-head"><em>Filling out this form won’t take too long, and the information you’ll receive may help you learn more about lowering your risk of HER2+ breast cancer recurrence.</em></td> </tr> <tr> <td width="100%"> <form> <div class="frm"> <div class="row"> <div class="col-md-3"> <label for="firstname">FIRST NAME:</label> <input type="firstname" class="form-control fld" id="firstname" placeholder="Enter First Name" required> </div> <div class="col-md-3"> <label for="email">EMAIL:</label> <input type="email" class="form-control fld" id="email" placeholder="Enter Email" required> </div> <div class="col-md-3"></div> <div class="col-md-3"></div> </div> <div class="row" style="margin: 20px 0 20px;"> <div class="col-md-3" style="padding: 0px; margin-top: -1px;">I have been diagnosed with:</div> <label class="col-md-3" style="user-select: none;"><input type="radio" name="patientorcarepartner" id="patient">Early-stage breast cancer</label> <label class="col-md-3" style="user-select: none;"><input type="radio" name="patientorcarepartner" id="carepartner">Metastatic breast cancer</label> <div id="errormsg" class="col-md-6">Please select one or both of these options</div> <div class="col-md-12" style="margin: 20px 0; padding: 0px;"> <table class="tbl-nopad"> <tr> <td valign="top"><input type="checkbox" value="Receive Updates" id="signup" checked></td> <td valign="top">In addition to receiving ReduceRecurrence.com communications, I would like to receive updates and information regarding other products and services from Puma Biotechnology, Inc.</td> </tr> <tr style="height:15px;"><td></td><td colspan="2"></td></tr> <tr><td colspan="3" valign="top">All information collected will be used for sending updates only and will not be shared with third parties other than those contracted with Puma to administer the website and authorized communications. For more details, see our <a href="http://www.pumabiotechnology.com/privacy_policy_20240301.html" target="_blank">privacy policy</a>.</td></tr> <tr><td colspan="3" style="text-align: center;"><input type="submit" class="form-control btn" id="submit" value="SUBMIT" disabled="disabled"></td></tr> </table> </div> </div> </div> </form></td> </tr> <tr> <td></td> </tr> </tbody> </table> </div>   <div style="background:#edf3fb;margin:0px auto;" class="form step3"> <table class="tbl"> <tbody> <tr> <td style="font-size: 33px; color: #737373; letter-spacing: 0; padding: 75px 0 50px;">Thank you for signing up to receive information from ReduceRecurrence.com.<br/> Keep an eye out for communications from us.</td> </tr> <tr> <td width="100%"> <form></form> </td> </tr> </tbody> </table> </div>   <div class="references"> <div class="wrapper"> <h2>References</h2> <div class="references-container"> <div class="ref-list"> <ul> <li><span class="num">1.</span>Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <em>Lancet</em>. 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-2.</li> <li><span class="num">2.</span>Breastcancer.org. U.S. breast cancer statistics. https://www.breastcancer.org/symptoms/understand_bc/statistics. Accessed March 5, 2021.</li> <li><span class="num">3.</span>Breastcancer.org. Non-invasive or invasive breast cancer. https://www.breastcancer.org/symptoms/diagnosis/invasive. Accessed March 5, 2021.</li> <li><span class="num">4.</span>Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. <em>N Engl J Med</em>. 2011;365(14):1273-1283. doi:10.1056/NEJMoa0910383.</li> <li><span class="num">5.</span>Herceptin [package insert]. South San Francisco, CA: Genentech, Inc. </li> <li><span class="num">6.</span>Herceptin Hylecta [package insert]. South San Francisco, CA: Genentech, Inc.</li> <li><span class="num">7.</span>Perjeta [package insert]. South San Francisco, CA: Genentech, Inc. </li> <li><span class="num">8.</span>Phesgo [package insert]. South San Francisco, CA: Genentech, Inc. </li> <li><span class="num">9.</span>Kadcyla [package insert]. South San Francisco, CA: Genentech, Inc. </li> <li><span class="num">10.</span>Breastcancer.org. Metastatic breast cancer. https://www.breastcancer.org/symptoms/types/recur_metast. Accessed March 5, 2021.</li> <li><span class="num">11.</span>von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. <em>N Engl J Med</em>. 2017;377(2):122-131. doi:10.1056/NEJMoa1703643.</li> </ul> </div> <div class="ref-list"> <ul> <li><span class="num">12.</span>von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. <em>N Engl J Med</em>. 2019;380(7):617-628. doi:10.1056/NEJMoa1814017.</li> <li><span class="num">13.</span>Mayo Clinic. Recurrent breast cancer. https://www.mayoclinic.org/diseases-conditions/recurrent-breast-cancer/symptoms-causes/syc-20377135. Accessed March 5, 2021.</li> <li><span class="num">14.</span>Breastcancer.org. Breast cancer risk factors. https://www.breastcancer.org/risk/factors. Accessed March 5, 2021.</li> <li><span class="num">15.</span>Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. <em>J Clin Oncol</em>. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730.</li> <li><span class="num">16.</span>U.S. Food and Drug Administration. Breast cancer public meeting on patient-focused drug development. https://www.fda.gov/media/129991/download. Accessed March 5, 2021.</li> <li><span class="num">17.</span>Fink MY, Chipuk JE. Survival of HER2-positive breast cancer cells: receptor signaling to apoptotic control centers. <em>Genes Cancer</em>. 2013;4(5-6):187-195. doi:10.1177/1947601913488598.</li> <li><span class="num">18.</span>Lin NU. Breast cancer brain metastases: new directions in systemic therapy. <em>Ecancermedicalscience</em>. 2013;7:307. doi:10.3332/ecancer.2013.307.</li> <li><span class="num">19.</span>Lin NU, Winer EP. Brain metastases: the HER2 paradigm. <em>Clin Cancer Res</em>. 2007;13(6):1648-1655. doi:10.1158/1078-0432.CCR-06-2478.</li> <li><span class="num">20.</span>Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. <em>Breast</em>. 2013;22(4):525-531. doi:10.1016/j.breast.2012.12.006.</li> </ul> </div> </div> </div> </div>  <footer style="clear:both;"> <div class="wrapper"> <div class=""><a href="http://www.pumabiotechnology.com/" target="_blank"><img src="img/puma-biotechnology.png"></a></div> <div class="copyright">This site is intended for US residents only.<br/>© 2022 Puma Biotechnology, Inc. All Rights Reserved.<br/> PRC-US-NER-2335 06/22</div> <div class="ftrlinks"> <a href="https://www.pumabiotechnology.com/privacy_policy_20240301.html" target="_blank">Privacy Policy</a><a href="https://www.pumabiotechnology.com/tos_20240301.html" target="_blank">Legal Notice</a><a href="http://www.pumabiotechnology.com/contacts.html" target="_blank">Contact Us</a></div> </div> </footer> <div class="popup interstitial"> <div class="content"> <h2>You are leaving<br>ReduceRecurrence.com</h2> <div> <button>STAY ON PAGE</button> <a>LEAVE PAGE</a> </div> </div> </div> </div>  </div>  <script type="text/javascript" src="js/vmasker.js"></script> <script type="text/javascript" src="js/form.js"></script> <script type="text/javascript" src="js/references.js"></script> <script type="text/javascript" src="js/anchor-scroller.js"></script> <script type="text/javascript" src="js/interstitial.js?v=1.0"></script> <script type="text/javascript" id="hs-script-loader" async defer src="https://js.hs-scripts.com/6895147.js"></script> </body> </html>